Literature DB >> 6236325

Captopril and immune regulation.

J F Delfraissy, P Galanaud, J F Balavoine, C Wallon, J Dormont.   

Abstract

We examined the in vitro effect of captopril (2.5 to 5 micrograms/ml) on the primary antibody response of human B cells. Captopril suppresses (by 50%) the specific anti-trinitrophenyl (TNP) response of unfractionated peripheral blood mononuclear cells (PBM) but not that of nonadherent PBM. The susceptibility to captopril suppression can be restored in the latter cell cultures by 10% adherent radioresistant cells. This suppression is independent of prostaglandins. In transfer experiments, cells preincubated with 5 micrograms/ml captopril suppress the antibody response of autologous nonadherent PBM. The inductive phase of this suppression requires both adherent cells and radiosensitive T cells. Once induced, the suppression can be transferred by isolated T effector cells. In vivo after a unique oral intake of captopril a moderate suppressor activity can be demonstrated in adherent cells from normal individuals. We conclude that captopril interferes with the immune regulation by inducing a suppressor circuit involving monocytes and a T8 suppressor effector lymphocyte.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6236325     DOI: 10.1038/ki.1984.111

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

Review 1.  Therapeutic approaches in mixed cryoglobulinemia.

Authors:  D Geltner
Journal:  Springer Semin Immunopathol       Date:  1988

Review 2.  Reappraisal of the clinical expression of mixed cryoglobulinemia.

Authors:  G Montagnino
Journal:  Springer Semin Immunopathol       Date:  1988

3.  A rat model of captopril immunogenicity.

Authors:  A L Foster; J W Coleman
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

Review 4.  Experimental mercury-induced glomerulonephritis.

Authors:  L Pelletier; F Hirsch; J Rossert; E Druet; P Druet
Journal:  Springer Semin Immunopathol       Date:  1987

5.  Antiproteinuric effect of captopril in a patient with lupus nephritis and intractable nephrotic syndrome.

Authors:  Y Shapira; F Mor; A Friedler; A J Wysenbeek; A Weinberger
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

6.  Drug-specific antibodies in patients receiving captopril.

Authors:  J W Coleman; J H Yeung; D H Roberts; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

7.  Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease.

Authors:  A Tarkowski; H Carlsten; H Herlitz; G Westberg
Journal:  Agents Actions       Date:  1990-08

8.  The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production.

Authors:  A C Peeters; M G Netea; B J Kullberg; T Thien; J W van der Meer
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

9.  Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis.

Authors:  Thomas J Bahk; Melvin D Daniels; Juan S Leon; Kegiang Wang; David M Engman
Journal:  Int J Cardiol       Date:  2007-06-22       Impact factor: 4.164

10.  Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis.

Authors:  A Fogo; Y Yoshida; A D Glick; T Homma; I Ichikawa
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.